Approaches, Challenges, and Advances in Metabolism of New Synthetic Cannabinoids and Identification of Optimal Urinary Marker Metabolites

@article{Diao2017ApproachesCA,
  title={Approaches, Challenges, and Advances in Metabolism of New Synthetic Cannabinoids and Identification of Optimal Urinary Marker Metabolites},
  author={Xingxing Diao and Marilyn A. Huestis},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2017},
  volume={101}
}
  • X. Diao, M. Huestis
  • Published 1 February 2017
  • Medicine, Biology
  • Clinical Pharmacology & Therapeutics
We review approaches for determining metabolism of new synthetic cannabinoids (SCs), and challenges and advances in identifying optimal urinary marker metabolites of SC intake. Metabolic patterns of different SC generations are evaluated, and a practical strategy offered for selecting SC urinary marker metabolites. Novel SCs are incubated with human hepatocytes, the most abundant and characteristic metabolites are identified with high‐resolution mass spectrometry, and proposed hepatocyte marker… 
View on Wiley
ncbi.nlm.nih.gov
64 Citations
Highly Influential Citations
2
Background Citations
18
Methods Citations
6
Results Citations
2

64 Citations

Citation Type

Citation Type

Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry
TLDR
The primary metabolites of EG-018 in human hepatocyte incubation were pentyl hydroxylated EG-18 (M6) and pentyl carbonylated EG-2018 (M8) and these two metabolites are proposed as the best urinary markers for confirming EG-019 intake.
New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites
TLDR
Current SC prevalence is reviewed, the necessity for SC metabolism investigation is established and the advantages and disadvantages of multiple metabolic approaches are compared, and a practical strategy to select optimal urinary marker metabolites for SCs is devised.
In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry
TLDR
The present study aims to recommend appropriate marker metabolites for documenting SDB-006 consumption by investigating its metabolism in human hepatocytes, and proposes 4′-keto-SDB-007 (M19) and pentyl-OH-SD B-006 (M15) as optimal marker metabolites.
Phase I-metabolism studies of the synthetic cannabinoids PX-1 and PX-2 using three different in vitro models
TLDR
PX-1 and PX-2 in vitro metabolites were revealed comprehensively by liquid chromatography–high-resolution mass spectrometry measurements and it is shown that all three in vitro assays are suitable for predicting metabolic pathways of synthetic cannabinoids.
In vivo and in vitro metabolism of the novel synthetic cannabinoid 5F-APINAC
TLDR
The discovered metabolites are proposed to be incorporated into routine screening analytical methods as the urine markers of 5F-APINAC consumption, and the predominant metabolic reaction was ester hydrolysis in both in vitro and in vivo experiments.
Synthetic cannabinoid BB‐22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography‐high resolution mass spectrometry detection
Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes
TLDR
Ten major metabolites of ADB-CHMINACA, a new synthetic cannabinoid with high potency and many reported adverse events and fatalities, are detected in hepatocyte incubations to identify its major metabolites and guide analytical standard manufacturers to better provide suitable references for further studies.
Synthetic cannabinoid receptor agonists and their human metabolites in sewage water: Stability assessment and identification of transformation products.
TLDR
The majority of investigated SCRAs, excluding the selected human metabolites, was recalcitrant to microbial degradation in sewage systems over a period of 29 days, and among the ten newly identified TPs three could be considered as relevant markers and should be included into future WBE studies to gain further insight into use and prevalence ofSCRAs on the drug market.
In vitro metabolic profiles of adamantyl positional isomers of synthetic cannabinoids
TLDR
The metabolism of ATHs is characterized for the first time and discriminated between the two isomers by mass spectrometric analysis of either the parent compounds or their major metabolites, demonstrating a useful method for distinguishing between AD isomers.
Comprehensive investigation on synthetic cannabinoids: metabolic behaviour and potency testing, using 5F-APP-PICA and AMB-FUBINACA as model compounds.
TLDR
A workflow for the comprehensive study of SC consumption is proposed and applied to 5F-APP-PICA and AMB-FUBINACA, based not only on the elucidation of their metabolites but also including functional data by the use of the NanoLuc approach, previously published.
...
...

References

SHOWING 1-10 OF 98 REFERENCES
Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices
TLDR
It is suggested that streamlined assessment of new SC’s pharmacokinetics and advanced HRMS screening provide a promising strategy to maintain relevant assays.
First Characterization of AKB-48 Metabolism, a Novel Synthetic Cannabinoid, Using Human Hepatocytes and High-Resolution Mass Spectrometry
TLDR
Using human hepatocytes and TripleTOF mass spectrometry, 17 novel phase I and II AKB-48 metabolites are identified, products of monohydroxylation, dihydroxylations, or trihydroxyation on the aliphatic adamantane ring or N-pentyl side chain.
First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry.
TLDR
These are the first data defining major urinary targets of XLR-11 metabolism that could document XLR -11 intake in forensic and clinical investigations.
Determination of AM-2201 metabolites in urine and comparison with JWH-018 abuse
TLDR
The presence of 6-indole hydroxylated metabolites of each drug and N-4-hydroxy metabolite of AM-2201 was found to contribute to the decisive differences in the metabolic patterns of the two drugs.
Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids.
TLDR
In vitro and in vivo metabolism of AM-2201 and forensic urine samples were analyzed and it has been shown that for both cannabimimetics the recommended screening targets are the monohydroxylated metabolites.
Metabolism and toxicological analysis of synthetic cannabinoids in biological fluids and tissues.
TLDR
This comprehensive review describes the history of the appearance of the drugs in the United States, discusses the naming conventions emerging to designate new structures, and describes the most prominent new compounds linked to the adverse effects now associated with their use.
In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200.
TLDR
The metabolite formed by consecutive morpholine cleavage and oxidation of the remaining side chain to a carboxylic group was detected in the highest amounts with the longest detection time and is the best candidate metabolite to detect JWH-200 abuse in urine.
Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry
TLDR
The main objective was to identify suitable analytical targets by analyzing human hepatocyte incubation samples with high-resolution mass spectrometry (HRMS) and to confirm the results in authentic urine specimens and to determine AB-FUBINACA's metabolic stability in human liver microsomes and compared hepatocyte and urine results with in silico predictions.
4-Methoxy-α-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry
TLDR
The most dominant metabolite in HLM and human hepatocyte samples was 4-hydroxy-α-PVP, also predicted as the #1 in silico metabolite, and is suggested to be a suitable analytical target in addition to the parent compound.
Metabolism of classical cannabinoids and the synthetic cannabinoid JWH‐018
TLDR
This brief review discusses the limited research on the metabolism of the SCB JWH‐018 and contrasts that with the metabolismOf Δ9‐THC and discusses the obvious potency and efficacy differences.
...
...